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Posttraumatic stress disorder (PTSD) is a debilitating condition that develops in some people after exposure to a traumatic event.
Brain-derived neurotrophic factor (BDNF) is highly expressed in the mammalian brain and is thought to be involved in learning
and memory processes. A nonsynonymous polymorphism in the BDNF gene, rs6265 (Val66Met), has been hypothesised to be
associated with PTSD. Association studies examining the Val66Met polymorphism and PTSD have been inconclusive, likely due
to the variability in type of trauma exposure analysed. Vietnam veterans (𝑛 = 257) screened for PTSD and controlled for trauma
exposure were genotyped for BDNF Val66Met.The association was not significant so we incorporated our data into ameta-analysis
to obtain greater statistical power. A comprehensive search of more than 1237 articles revealed eight additional studies suitable
for meta-analysis (𝑛 = 3625). A random-effects meta-analysis observed a potential protective factor of the Val/Val genotype.
After removing two studies with violation of Hardy-Weinberg equilibrium, findings for the Val/Val genotype reached significance.
Subgroup analyses confirmed a trend for this finding. Limitations of some studies that inform this meta-analysis include poorly
screened controls and a lack of examination of population stratification. Effectively designed studies should inform this line of
research in the future.
1. Introduction
Posttraumatic stress disorder (PTSD) is a debilitating con-
dition following from the experience of a severe traumatic
event [1]. PTSD onset can be close to the traumatic event or
delayed, and a majority of the population will never present
with PTSD despite similar traumatic exposure [2].Why some
people develop clinical symptoms of PTSD while others do
not is still unknown.
Memory processes such as recurring fearful memories
and nightmares are central to PTSD symptomatology as they
underpin the establishment of exacerbated fear responses
(e.g., hypervigilance and startle, reviewed in [3]). The inabil-
ity to extinguish fear response is thought to be fundamental
to the persistence of the disorder [4], increasing anxiety states
and perpetuating stress. Research on animal models and
genetic predisposition in humans has identified a potential
vulnerability to the establishment of fear memories and
difficulties to subsequently extinguishing them, for example,
Felmingham et al., 2013 [5].
Investigations of biological factors commonly associated
with learning and memory formation have indicated that
brain-derived neurotrophic factor (BDNF) may be a promis-
ing candidate. BDNF is a neurotrophin mediating synaptic
plasticity [6]. It is highly expressed in the mammalian
brain, especially in the hippocampus, which is functionally
associated with learning and memory processes, reviewed in
Yamada and Nabeshima [7]. Its binding to TrkB (tyrosine
receptor kinase) causes intracellular cascades affecting neu-
ronal development, plasticity, long-term potentiation, and
apoptosis [8, 9]. The polymorphism rs6265, also known as
Val66Met, of BDNF has been hypothesised to be important
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in fear learning and has shown some promising associations
in animal models, reviewed in Andero and Ressler, 2012
[3]. The Met/Met genotype is associated with increased
PTSD susceptibility, compromised memory performance,
and reduced gene expression [10]. Reduced gene expression
has been associated with reduced hippocampal volumes in
animal models [10] and humans with PTSD [11].
Due to these findings and the role of fear memories in
the development and maintenance of PTSD, research with
human participants has attempted to identify associations
between BDNF Val66Met and PTSD, but findings have been
inconsistent. An intensive literature search across several
databases with no language restriction yielded eight asso-
ciation studies of PTSD and Val66Met. Seven out of the
eight studies did not find a significant association between
the Met/Met genotype and PTSD. In the broader litera-
ture for Val66Met and disorders with high overlap with
PTSD (e.g., depression and anxiety disorders), findings are
equally mixed, for example, [12–14]. A meta-analysis of
BDNF Val66Met and association with PTSD did not find an
association overall but only in subgroup analyses for trauma
exposed controls [15]. However, the researchers classified the
study by Zhang et al. (2006) [16] as mixed race even though
the study reported the population as European American.
The authors also noted that the limited amount of studies
reduced statistical power to detect an effect due to the relative
rarity of the Met allele [15]. In summary, research into
Val66Met and PTSD is inconclusive.
A case-control study was performed with participants
who were thoroughly screened for trauma exposure and
ethnicity and explored the role of BDNF Val66Met in PTSD.
The results were added to a meta-analysis to expand on
the findings from a previous meta-analysis of Val66Met and
PTSD [15] in order to achieve higher statistical power to
detect an effect. Based on previous studies in animal models
[3] and with human participants, the hypothesis is that
individuals carrying the Met allele will be at a higher risk of
PTSD than those with the Val allele [10].
2. Methods
2.1. Case-Control Study
2.1.1. Participants. For the case-control study, participants
(𝑛 = 299) were sourced through a veterans hospital and
the Returned and Services League of Australia with the
aim of recruiting approximately equal group sizes for cases
and controls. Inclusion requirements were deployment to
Vietnam and being of Caucasian ethnicity; the only exclusion
criterion was absence of trauma exposure (𝑛 = 32). As a
pair of identical twins had participated, the information for
one of the twins was not included. All included participants
were male (𝑛 = 265). All participants were evaluated
through semistructured interviews by trained psychiatrists
at the hospital. A total of 158 participants were diagnosed
with PTSD, with 107 with trauma exposure but no PTSD
symptoms. Further nine participants were excluded due to
ethnicity (𝑛 = 3) and problems with genotype calls (𝑛 = 6)
resulting in a final cohort of 𝑛 = 257 (PTSD: 𝑛 = 151; no
PTSD: 𝑛 = 106) for chi-square analysis.
2.1.2. Scales. Severity of PTSD was assessed by trained
psychologists with the Clinician Administered PTSD Scale
for DSM V [17], the gold standard procedure for PTSD
assessment. Comorbidities were assessed using the Mini
International Neuropsychiatric Interview (MINI), an instru-
ment designed to assess major Axis 1 disorders in the DSM
IV with high validity and reliability [18, 19].
2.1.3. Genotyping. Blood samples were sent to the Australian
Genome Research Facility (AGRF) for DNA extraction and
genotyping. Upon arrival, samples were stored at −20∘C. Ge-
nomic DNA was extracted from a 2mL blood sample, using
MACHEREY-NAGEL NucleoSpin L (MACHEREY-NAGEL
GmbH & Co. KG, Du¨ren, NRW, Germany). Quality of the
DNA was assessed through resolution on a 0.8% agarose gel
at 130V for 60 minutes. Samples were normalised to 200 ng
of DNA in 4 𝜇L.
Genotyping was performed using the Illumina PsychAr-
ray-24 BeadChip scanned with the Illumina iScan systems.
Data analysis was performed usingGenomeStudio v2011.1 (Il-
lumina, San Diego, CA, USA) with Genotyping Module 1.9.4
software. Default settings by Illumina, the InfiniumPsy-
chArray-24v1-1 A1 manifest and Infinium PsychArray-24v1-
1 A1 ClusterFile cluster files, were applied. Across the entire
array eight samples fell below the SNP call rate of 99% with
the lowest call rate being 87% (range: 87% to 98%). Eleven
samples were performed in duplicate for quality assurance
with 100% reproducibility rate for Val66Met.
2.1.4. Statistical Analysis. WinPEPI computer program for
epidemiologists was used to calculate chi-squares, odds
ratios, and 95% confidence intervals [20]. Hardy-Weinberg
equilibrium (HWE) statisticswere calculated using theUtility
Programs for Analysis of Genetic Linkage [21]. All other
analyses were conducted using SPSS Statistics Package 23 for
Windows computers.
2.2. Meta-Analysis
2.2.1. Literature Searches. Literature searches were conducted
using the PubMed, PsycINFO, and PILOT databases to
February 2016. No limitation for type of publication, lan-
guage, or publication timeframe was set. Searches using
the terms “PTSD,” “BDNF,” “rs6265,” and “Val66Met” in
combination and separately were conducted and cross-
referenced. Additional Google scholar alerts were set for the
keywords PTSD and BDNF but did not yield further eligible
studies. In addition, authors of relevant studies and known
researchers in the fieldwere contacted for potential additional
information or unpublished data. One author group [22]
provided additional information as participant recruitment
had continued after their study results were published. The
additional information was incorporated into the dataset of
the originally published study [22] and the updated data
were included in the current meta-analysis. The inclusion
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of additional data in the study did not change the overall
findings of the original study. Another author group had
reported on the role of BDNF Val66Met in a longitudinal
study about the Wenchuan earthquake and the trajectory
of PTSD symptom severity over the course of 18 months
[23]. Upon request the authors kindly sent the genotype
information for the cases and controls that had not been
reported in the published paper. Lastly, our own data from
the current case-control study were integrated in the meta-
analysis.
Beyond the database searches, reference lists of all articles
obtained were perused to identify additional studies. Arti-
cles were cross-referenced to ensure that independence of
datasets was maintained; that is, publication duplication of
the same data was controlled for.
In order to be included, studies had to be performed with
human participants and had to use a case-control research
design for associations with PTSD. Eight studies for PTSD
and our own data met the inclusion criteria for analysis.
Table 1 lists all selected studies, their basic characteristics,
genotype count, and HWE calculations.
2.2.2. Statistical Analysis. Microsoft Excel was used to calcu-
late individual odds ratios, log ratios, log standard errors, and
95% confidence intervals for each of the studies based on the
formulae previously published [24]. Because not all studies
reported HWE and one study had additional participants not
previously reported, HWE statistics were calculated for all
studies using the Utility Programs for Analysis of Genetic
Linkage [21]. 𝑄 homogeneity tests were conducted to deter-
mine heterogeneity of effect size estimates [25]. Heterogene-
ity variedwidely depending on inclusion or exclusion of stud-
ies in the main analyses and subanalyses. Hence, both fixed-
effects and random-effects models were applied to calculate
the combined odds ratio per genotype and on an allele basis
as previously published [24], and subgroup analyses were
performed to achieve refined data. The following analyses
were pursued: for genotype analysis Val/Val genotype was
compared to Val/Met and Met/Met. We also performed
dominant and recessive analyses (Met/Met against pooled
Val/Val and Val/Met and Val/Val against pooled Met/Met
and Val/Met, resp.) both for individual studies and the
combined meta-analysis. Furthermore, analyses on an allele
level were performed, contrasting the risk allele (Met) against
the Val allele. While the emphasis of this paper lies with
the findings from the random-effects model due to its more
conservative nature, findings from the fixed-effects model
are presented, where heterogeneity was low-to-moderate.
All data from the fixed-effects model (Table S1 and Table
S2) can be found in the Supplementary Material available
online at http://dx.doi.org/10.1155/2016/6979435. Fail Safe 𝑁
was calculated [26]. This statistic indicates stability of the
result under the assumption that study results may have
been missed from the meta-analysis. Fail Safe 𝑁 estimates
the number of contradictory results needed to reverse the
statistical significance of the meta-analytic effect size.
Due to the relatively small number of studies in this
meta-analysis and given that the majority of the studies
reported nonsignificant findings, publication bias could not
be observed. Hence, further investigations of publication bias
through funnel plots were not pursued.
3. Results
3.1. Case-Control Study. Table 2 shows an overview of the
study cohort demographics and comorbidities by diagnosis.
An independent 𝑡-test revealed nonsignificant differences
for age (𝑡(265) = 1.274; 𝑝 = 0.204) but, as would be
expected, there were significant differences in CAPS severity
scores between the PTSD and the no-PTSD group: 𝑡(262) =
−13.348; 𝑝 = 0.000. As expected, the distribution of the
CAPS severity scores across the entire cohort was not normal
and a nonparametric test (Kruskal-Wallis) was performed to
identify potential differences between genotypes and CAPS
severity. The test revealed a nonsignificant result: 𝑝 = 0.345.
To account for potential genotype associations within the
PTSD group with regard to symptom severity, we performed
an ANOVA with the patient cohort only, but the result was
also nonsignificant: 𝐹(2) = 0.501; 𝑝 = 0.607.
The PTSD and no-PTSD groups were both in HWE. The
contingency table (Table 3) shows that all observations were
above 5.The results for the chi-square test were not significant
(𝜒2(2) = 1.225; 𝑝 = 0.54). Analysis based on allele frequency
was also nonsignificant.
3.2. Meta-Analysis. Table 4 lists the individual studies with
their respective converted odds ratios and confidence inter-
vals for analysis of Val/Val genotype against heterozygous
genotype and Met/Met genotype, respectively. Overall, the
meta-analysis included 3625 participants, of which 1066 were
cases and 2559 were controls. Of the 2559 controls, 1379
were trauma-exposed but had not developed symptoms of
PTSD. The remaining 1180 control subjects were unscreened
for trauma exposure. As had been reported by the respective
authors and has been found with our own data, eight
studies show nonsignificant results for an association of
Val66Met with PTSD across the three genotypes. The only
study showing significant results is the study by Zhang et
al. [27]. However, HWE calculations in this study indicated
that the control group was not in HWE (𝑝 = 0.005).
We also ran all studies through dominant, recessive, and
allelic analyses (Table 5). In these analyses, the same study
[27] yielded significant results in the dominant and allele
analyses. A further study was approaching significance in
the dominant and allele analyses as well [23]. For this study,
Hardy-Weinberg equilibrium was maintained. The subgroup
analysis in Valente et al. [28] for trauma-exposed individuals
also revealed a significant result but should be interpreted
with caution due to the very low number of controls (𝑛 = 34)
and the fact that this result could not be confirmed by analysis
on an allele level. Similarly, we observed a significant effect in
another study [29] for the dominant analyses but again this
result was not confirmed by allelic analysis and the patient
cohort was not in HWE.
For the overall meta-analysis, 𝑄 homogeneity analysis
revealed high heterogeneity when all studies were included
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Table 2: Demographics and clinical summary.
PTSD No PTSD
Age (M, SD) 68.47 (4.18) 69.13 (4.14)
Education level (counts)
Less than year 10 26 6
Year 10 29 15
Vocational 32 17
Year 11 or 12 34 27
University 36 44
Direct combat experience
(counts) Yes: 137; no: 21 Yes: 85; no: 24
CAPS mean scores (SD) 15.71 (9.78) 2.68 (3.71)
Comorbidities (counts)1
Major depression 21 1
Dysthymia 19 3
Suicide risk 31 1
Agoraphobia 33 6
Social phobia 8 0
Alcohol dependence 22 5
Alcohol abuse 3 1
Substance dependence 1 0
Substance abuse 0 0
Generalised anxiety disorder 12 2
Note. M, mean; SD, standard deviation; 1all comorbidity counts as per Mini
International Neuropsychiatric Interview (MINI) for DSM IV [18, 19]. Only
a subset of all comorbidities was shown. Rare comorbidities with no current
information or both groups = 0 were excluded from the table.
(Table 6). The random-effects model yielded nonsignificant
results (Table 6). Because of the previously reported issues
with HWE in both Zhang et al. (2014) [27] and Dretsch
et al. [29], the studies were removed in two steps. Initially,
only the study with HWE problems in the control cohort
[27] was removed. The random-effects model remained
nonsignificant. When the study with HWE problems in the
patient cohort was also removed, a significant result was
observed for the Val/Val genotype against the heterozygous
genotype (Table 6). Similarly, for the recessive and dominant
models, results remained nonsignificant when only the study
with HWE deviation in the control group was removed [27].
However, the recessive model almost reached significance
(OR= 0.90; CI 95% [0.81; 1.00]) after both studies withHWE
problems were removed. The dominant model as well as the
allelic model remained nonsignificant. Heterogeneity in the
allelic model dropped to a moderate level when only Zhang
et al. 2014 [27] was removed and also when both studies with
HWEviolationswere removed, and so the fixed-effectsmodel
was consulted as well. In both cases the fixed-effects model
for allele analysis almost reached significance (OR = 1.12; CI
95% [0.97; 1.28] and OR = 1.10; CI 95% [0.96; 1.27], resp.; see
Table S1). Fail Safe𝑁was calculated indicating that about one
study was needed to overturn the results of the overall meta-
analysis with and without the studies with HWE violation.
Fail Safe𝑁 information can be found in Table 6.
Due to differences in the genotype frequencies across
ethnicities [32], subgroup analyses were conducted. Three
studies included Caucasian participants [16, 22] and our
own data; three studies included Asian participants [23,
30, 31]. The other three remaining studies had different
mixed ethnic groups and were excluded from this subgroup
analysis.The analysis for Caucasian ethnicity showed that the
recessive model was approaching significance (OR = 0.92; CI
95% [0.84; 1.01]). Both the dominant and the allelic models
had low-to-moderate heterogeneity and the fixed-effects
model was pursued but no significant findingswere observed.
For the Asian group, analyses revealed nonsignificant results
across all models in the random-effects meta-analysis. How-
ever, heterogeneity analysis revealed low heterogeneity of the
recessivemodel (Val/Val:𝑄 = 2.55,𝑝 < 0.05; 𝐼2 = 21.58).The
fixed-effects model was approaching significance (OR = 0.79;
CI 95% [0.57; 1.09]; Table S2). All results for the random-
effects model on ethnicity can be found in Table 7.
Four studies [22, 27, 29], including our current case-
control study, reported using a control group with trauma
exposure but no PTSD diagnosis (𝑛 = 638, 𝑛 = 461,
𝑛 = 226, and 𝑛 = 257, resp.). Valente et al. (2011) [28]
employed two control groups, a smaller one with trauma
exposure and no PTSD symptomatology (𝑛 = 34) and a
larger one of unscreened controls (𝑛 = 733). Hence, only
the trauma-exposed subgroup was used for this subanalysis.
As the subgroup analyses for trauma-controlled cohorts
contained two studies deviating from HWE, these studies
were removed in two steps. The findings for the random-
effects model remained nonsignificant across all analyses
when all studies were included and when only Zhang et al.
(2014) [27] was removed. We pursued the fixed-effects model
in the recessive analysis in this step and heterogeneity was
low-to-moderate (Val/Val: 𝑄 = 5.17, 𝑝 < 0.05; 𝐼2 = 42.00),
and the fixed-effects model was approaching significance
(OR = 0.85; CI 95% [0.69; 1.06]). When both studies devi-
ating from HWE were removed, analysis of Val/Val against
heterozygous genotype was approaching significance (OR =
0.84; CI 95% [0.66; 1.08]), a finding that was confirmed by
the fixed-effects model (OR = 0.84; CI 95% [0.67; 1.07]). The
recessive analysis was nonsignificant in the random-effects
model but revealed moderate heterogeneity and the fixed-
effects model was approaching significance (OR = 0.85; CI
95% [0.67; 1.06]; Table S2).
4. Discussion
A case-control study and meta-analysis were conducted to
investigate the role ofBDNFVal66Met in PTSD susceptibility.
This polymorphism has been implicated in the susceptibility
to PTSD due to its association with decreased brain-derived
neurotrophic factor levels leading to altered memory forma-
tion and brain volume, for example, [33]. Reduced hippocam-
pal volumes have been observed in patients diagnosed with
PTSD [11].
Our case-control study provided a tightly screened cohort
for analysis. However, our study did not reach significance
likely due to the sample size and low Met/Met genotype
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Table 3: Association of genotype frequencies of BDNF Val66Met for participants with and without PTSD.
Val66Met Genotype counts (%) 𝑝 value Allele count
Val/Val Val/Met Met/Met Val Met
PTSD 99 (65.62) 46 (30.5) 6 (4.0) 0.542∗ 244 58
No PTSD 71 (67.0) 28 (26.4) 7 (6.6) 0.435∗∗ 170 42
Odds ratio (𝑝 value) 1 1.178 (0.811) 0.615 (0.639) 0.96CI 95% [0.62; 1.50] 1
Note. ∗𝑝 value determined by Pearson’s 𝜒2 test; ∗∗𝑝 value determined by Mantel-Haenszel test for trend in a given direction.
Table 4: Individual studies with their respective odds ratios and 95% confidence intervals.
Study Val66Met Genotype counts 𝑝 value
Val/Val Val/Met Met/Met
Zhang et al., 2006 [16]
PTSD 69 (71.88) 26 (27.08) 1 (1.04)# 0.306∗
No PTSD 166 (66.40) 74 (29.60) 10 (4.00) 0.097∗∗
Odds ratio (𝑝 value) 1 0.845 (0.779) 0.241 (0.202)
Lee et al., 2006 [30]
PTSD 28 (26.17) 57 (53.27) 22 (20.56) 0.809∗
No PTSD 48 (29.81) 82 (50.93) 31 (19.25) 0.282∗∗
Odds ratio (𝑝 value) 1 1.192 (0.797) 1.217 (0.834)
Valente et al., 2011 [28]
All controls
PTSD 48 (73.85) 15 (23.08) 2 (3.08)# 0.756∗
No PTSD 584 (76.14) 169 (22.03) 14 (1.83) 0.284∗∗
Odds ratio (𝑝 value) 1 1.080 (0.962) 1.738 (0.751)
Controls only
PTSD 48 (73.85) 15 (23.08) 2 (3.08)# 0.800∗
No PTSD 555 (75.72) 164 (22.37) 14 (1.91) 0.314∗∗
Odds ratio (𝑝 value) 1 1.058 (0.980) 1.652 (0.788)
PTSD− only
PTSD 48 (73.85) 15 (23.08) 2 (3.08)# 0.333∗
No PTSD 29 (85.29) 5 (14.71) 0 (0.00)# 0.075∗∗
Odds ratio (𝑝 value) 1 1.165 (0.482) 1.860 (0.316)
Lyoo et al., 2011 [31]
PTSD 10 (33.33) 15 (50.00) 5 (16.67) 0.775∗
No PTSD 14 (38.89) 18 (50.00) 4 (11.11)# 0.253∗∗
Odds ratio (𝑝 value) 1 1.167 (0.950) 1.750 (0.725)
Pivac et al., 2012 [22]
PTSD 235 (63.00) 126 (33.78) 12 (3.22) 0.702∗
No PTSD 173 (65.28) 86 (32.45) 6 (2.26) 0.229∗∗
Odds ratio (𝑝 value) 1 1.079 (0.884) 1.472 (0.687)
Zhang et al., 2014 [27]
PTSD 20 (47.62) 16 (38.10) 6 (14.29) 0.004∗
No PTSD 294 (70.17) 104 (24.82) 21 (5.01) 0.000∗∗
Odds ratio (𝑝 value) 1 2.262 (0.048) 4.200 (0.023)
Li et al., 2016 [23]
PTSD 39 (24.22) 80 (49.69) 42 (26.09) 0.159∗
No PTSD 109 (29.46) 190 (51.35) 71 (19.19) 0.033∗∗
Odds ratio (𝑝 value) 1 1.177 (0.725) 1.653 (0.120)
Dretsch et al., 2016 [29]
PTSD 28 (68.29) 8 (69.73) 5 (12.20) 0.077∗
No PTSD 129 (69.73) 49 (26.49) 7 (3.78) 0.163∗∗
Odds ratio (𝑝 value) 1 0.752 (0.755) 3.291 (0.129)
Our study
PTSD 99 (65.62) 46 (30.5) 6 (4.0) 0.542∗
No PTSD 71 (67.0) 28 (26.4) 7 (6.6) 0.435∗∗
Odds ratio (𝑝 value) 1 1.178 (0.811) 0.615 (0.639)
Note. #At least one cell count less than 5; ∗𝑝 value determined by Pearson’s 𝜒2 test; ∗∗𝑝 value determined byMantel-Haenszel test for trend in a given direction;
significant findings are in bold.
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Table 5: Individual studies, their odds ratios, and 95% confidence
intervals for recessive and dominantmodels on a genotype basis and
on an allele model.
Study Model Odds ratios 95% CI
Zhang et al., 2006 [16]
Recessive 1.30 0.77; 2.17
Dominant 0.25 0.03; 2.00
Allele 0.74 0.47; 1.17
Lee et al., 2006 [30]
Recessive 0.83 0.48; 1.44
Dominant 1.09 0.59; 2.00
Allele 1.10 0.78; 1.56
Valente et al., 2011 [28]
All controls
Recessive 0.88 0.50; 1.57
Dominant 1.71 0.38; 7.68
Allele 1.15 0.69; 1.92
Controls only
Recessive 0.91 0.51; 1.61
Dominant 1.63 0.36; 7.33
Allele 1.13 0.68; 1.88
PTSD− only
Recessive 0.49 0.16; 1.46
Dominant 0.08 0.02; 0.36
Allele 2.16 0.77; 6.05
Lyoo et al., 2011 [31]
Recessive 0.79 0.29; 2.16
Dominant 1.60 0.53; 3.88
Allele 1.26 0.63; 2.55
Pivac et al., 2012 [22]
Recessive 0.91 0.65; 1.29
Dominant 1.43 0.53; 3.87
Allele 1.11 0.84; 1.47
Zhang et al., 2014 [27]
Recessive 0.39 0.20; 0.73
Dominant 3.16 1.20; 8.33
Allele 2.37 1.46; 3.86
Li et al., 2016 [23]
Recessive 0.77 0.50; 1.17
Dominant 1.49 0.96; 2.30∗∗
Allele 1.28 0.98; 1.66∗∗
Dretsch et al., 2016 [29]
Recessive 0.94 0.45; 1.94
Dominant 3.53 1.06; 11.75
Allele 1.37 0.76; 2.47
Our study
Recessive 0.94 0.55; 1.59
Dominant 0.59 0.19; 1.79
Allele 0.96 0.62; 1.50
Note. Significant findings are in bold; ∗∗approaching significance.
frequencies. This is in line with other studies published in
this area, for example, [22]. We also could not establish
differences in PTSD symptom severity by genotype, probably
also due to sample size restriction and an additional loss
of power with the use of a nonparametric test to account
for the violation of normality in score distribution. Group
differences in symptom severity between those diagnosed
with PTSD and those with trauma exposure but no PTSD
diagnosis were significant as would be expected.
Our data were used in a meta-analysis in an attempt to
increase statistical power and evaluate the involvement of
Val66Met in PTSD. Based on literature on animal and human
studies, individuals with the Met allele were hypothesised to
be associatedwith a higher likelihood of PTSDdiagnosis than
those with the Val allele. The overall meta-analysis revealed
high heterogeneity of data and did not reveal a significant
association. However, findings differed when two studies
were removed because of deviating from HWE [27, 29].
We observed a significant effect in the overall analysis for a
decreased risk of PTSD for the Val/Val genotype compared
to the heterozygous genotype, albeit with a small effect size.
A trend for a significant effect of the recessive model was
also observed in the recessive analysis indicating that the
Val/Val genotype may have protective properties towards the
development of PTSD.
This trend was also observed in our subgroup analysis for
ethnicity with an approach to significance for the Caucasian
cohort in a random-effects model as well as for the Asian
cohort in the fixed-effects model. Similarly, we found a
trend for protective properties of the Val/Val genotype in the
analysis with trauma-exposed controls only.
The results of thismeta-analysis alter some of the findings
of a previous meta-analysis using a random-effects model
[15]. We expanded findings from that study with the addition
of 𝑛 = 1071 participants including our own study, a study on a
Han-Chinese population [23], a mixed ethnicity but trauma-
controlled study [29], and additional data for Caucasian
participants [22]. We also applied a fixed-effects model to
show potential trends. Our results show a trend towards
an association of BDNF Val66Met with PTSD with the
Val/Val genotype potentially exhibiting a protective factor.
The previously published study could only find an effect
of the polymorphism in the subgroup analysis for trauma
exposure indicating an increased risk for Met carriers [15].
Our findings with regard to the protective mechanism of the
Val/Val genotype are probably due to the higher occurrence
of the Val allele in the general population as opposed to
the relatively rare Met allele (Val allele, 80%, and Met allele,
20%, in a European population; see NCBI database [34]).
We reported the fixed-effects model in our Results only in
cases where heterogeneity was moderate-to-low. However,
examination of the fixed-effects model across all analyses
reveals a much stronger trend towards an involvement of the
polymorphism in PTSD.
Even though we were able to add substantially to the
meta-analysis, our results need to be interpretedwith caution.
Fail Safe 𝑁 revealed that a very small number of studies
can overturn the observed results which is not surprising
given the small amount of studies published in this area
so far. Clearly characterised study cohorts would enhance
research in this area. The significant differences in Met/Met
genotype distribution between ethnicities [32] underline
the importance of designing ethnically controlled studies.
Research with other genes has shown that ethnicity can play
an important role in associations studies with significant
results restricted to one specific ethnic group. One study, for
example, found significant results only for a non-Hispanic
black cohort of war veterans as opposed to non-Hispanic
white veterans for the 5-HTTLPR polymorphism of the
serotonin transporter gene SLC6A4 [35]. Trauma type has
been shown to influence likelihood of PTSD diagnosis [2]
and PTSD severity differentially by gender [36] with PTSD
rates within military samples being generally high (for an
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Table 6: Results of the overall meta-analysis including all studies and stepwise removal of Zhang et al. (2014) [27] and Dretsch et al. (2016)
[29] in a random-effects model.
Analysis Model Odds ratio 95% CI 𝐼2 Fail safe𝑁
All studies
Val/Val versus Val/Met 0.92 0.57; 1.47 82.87 N/A
Val/Val versus Met/Met 0.87 0.15; 4.97 96.28 N/A
Recessive 0.87 0.56; 1.34 89.35 N/A
Dominant 1.44 0.61; 3.38 86.99 N/A
Allele 1.20 0.65; 2.20 95.02 1.20
Zhang et al. (2014) [27] removed
Val/Val versus Val/Met 0.97 0.70; 1.36 62.25 N/A
Val/Val versus Met/Met 1.02 0.19; 5.56 95.51 0.14
Recessive 0.65 0.39; 1.10 N/A N/A
Dominant 1.24 0.60; 2.60 78.30 1.46
Allele 1.10 0.88; 1.37 55.34 0.60
Zhang et al. (2014) [27] and Dretsch et al. (2016) [29] removed
Val/Val versus Val/Met 0.82 0.70; 0.96 N/A N/A
Val/Val versus Met/Met 1.22 0.19; 7.66 95.79 1.10
Recessive 0.90 0.81; 1.00∗∗ N/A N/A
Dominant 1.07 0.48; 2.39 81.40 0.37
Allele 1.08 0.85; 1.35 58.51 0.38
Note. Significant findings are in bold; ∗∗approaching significance.
Table 7: Results from the subgroup analyses with and without Zhang et al. (2014) [27] and Dretsch et al. (2016) [29] from the random-effects
model.
Analysis Model Odds ratio 95% CI 𝐼2 Fail Safe𝑁
Ethnicity
Caucasian
Val/Val versus Val/Met 1.14 0.84; 1.55 N/A 0.71
Val/Val versus Met/Met 1.72 0.00; 652.97∗ 98.46 3.60
Recessive 0.92 0.84; 1.01∗∗ N/A N/A
Dominant 0.73 0.26; 2.09 48.90 N/A
Allele 0.96 0.73; 1.27 35.96 N/A
Asian
Val/Val versus Val/Met 0.80 0.57; 1.11 N/A N/A
Val/Val versus Met/Met 0.67 0.20; 2.19 83.90 N/A
Recessive 0.79 0.54; 1.16 21.58 N/A
Dominant 1.34 0.53; 3.39 80.38 1.71
Allele 1.20 0.70; 2.08 82.22 1.04
PTSD−
Val/Val versus Val/Met 0.86 0.40; 1.84 89.50 N/A
Val/Val versus Met/Met 0.61 0.09; 4.00 95.33 N/A
Recessive 0.70 0.30; 1.68 93.48 N/A
Dominant 0.96 0.009; 10.65 97.09 N/A
Allele 1.44 0.55; 3.78 96.91 2.64
PTSD−
Zhang et al. (2014) [27] removed
Val/Val versus Val/Met 0.95 0.54; 1.68 69.17 N/A
Val/Val versus Met/Met 0.66 0.18; 2.55 88.64 N/A
Recessive 0.85 0.65; 1.10 22.69 N/A
Dominant 0.71 0.04; 11.63 97.19 N/A
Allele 1.24 0.83; 1.83 76.44 1.41
PTSD−
Zhang et al. (2014) [27] and Dretsch et al. (2016) [29]
removed
Val/Val versus Val/Met 0.84 0.66; 1.08∗∗ 6.22 N/A
Val/Val versus Met/Met 0.85 0.26; 2.80 84.52 N/A
Recessive 0.82 0.60; 1.15 42.00 N/A
Dominant 0.57 0.03; 11.16 97.59 N/A
Allele 1.21 0.77; 1.91 80.97 1.06
Note. ∗∗Approaching significance; ∗very wide confidence intervals potentially due to frequencies.
Neural Plasticity 9
extensive review see [37]) and hence needs to be controlled
for in future studies. Because of the significance of memory
formation in the development of PTSD, screened controls,
ideallywith the sameor similar trauma exposure, are required
to determine an effect of the polymorphism in PTSD. We
could not perform a subanalysis based on gender as gender
type was not available in all studies. Research has suggested
higher susceptibility [38] and heritability [39] for PTSD in
women and trauma type influences PTSD diagnosis and
severity differentially in women [36]. Gender based study
cohorts would further improve research in this field.
5. Conclusion
This meta-analysis showed a trend for the involvement of
BDNF Val66Met in PTSD. The trend shows a potential
protective factor of the Val/Val genotype and in a fixed-effects
model a trend for PTSD risk in Met carriers. However, the
systematic investigation of published studies so far revealed
that research in this area would benefit greatly from more
clearly designed studies in terms of ethnic and control group
definitions. It will be important to further research on the
involvement of Val66Met in PTSD due to its potential role
in fear memory formation and its interactions with the stress
cascade.
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